A noninvasive molecular test identifies patients more likely to respond to JAK inhibitors versus Th2-targeted therapies, potentially accelerating clearance and reducing treatment switches.
Two new clinical analyses examine how simultaneous, on-label 64-unit onabotulinumtoxinA treatment of the upper face delivers natural-looking, durable, and predictable outcomes across diverse patient populations and multiple treatment cycles.
If approved, upadacitinib will be the first systemic medication available for patients with vitiligo, according to the company.
The device is designed for use in areas with slightly thicker skin and is intended for applications such as non-surgical hair restoration.
rater8 has introduced AI Insights, a conversational AI feature within its raVE platform that allows healthcare practices to query and quickly extract actionable answers from their patient feedback data.
